A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Osteoporosis, Postmenopausal

In brief

The purpose of this study is to evaluate the tolerability of two different formulations of blosozumab in women who have reached menopause. This study will last approximately 12 weeks for each participant, not including screening. Screening is required within 28 days prior to starting the study.

Key facts

Study ID

NCT02337387

Run by

Eli Lilly and Company

People needed

28

Starts

2015-01-01

Expected to finish

2015-03-01

Last updated by the study team

2019-01-22

Who can join

Age: 45 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Part A: Overtly healthy postmenopausal (PMP) females
• Part B: PMP women who are currently taking oral bisphosphonates for prevention or treatment of osteoporosis
• Have a body mass index (BMI) at screening of 19.0 to 35.0 kilogram per square meter (kg/m\^2)

You may not qualify if…

• Have known allergies to blosozumab, its constituents, or related compounds
• Have an abnormality in the 12-lead electrocardiogram (ECG)
• History of breast carcinoma
• Fracture of a long bone within 1 year of screening
• Have used teriparatide within 3 years prior to screening

Where it is running

• Covance — Daytona Beach, Florida, United States
• Covance Clinical Research Inc — Evansville, Indiana, United States
• Covance — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.